We conducted a double-blind study to determine the efficacy of 17alpha-hydroxyprogesterone caproate in preventing premature delivery in 43 high-risk patients. Premature delivery did not occur in 18 patients receiving the progestational agent, whereas 41 per cent of the 22 receiving the palcebo had premature delivery (P less than 0.01). The mean duration of pregnancy and the mean birth weight in the former group (38.6 weeks +/- 1.6 S.D., and 2836 g +/- 412 S.D.) were both significantly greater (P less than 0.025) than that in the latter (35.2 weeks +/- 6.7 S.D.; 2361 g +/- 1085 S.D.). The perinatal mortality rate in the group given the progestational agent (O per cent) was significantly less than that observed in the placebo group (27 per cent) (P less than 0.05). Although there were no complications attributable to the progestational drug, the study population was too small for assessment of immediate or long term safety. However, the results indicate a possible obstetric use for this drug.
This article has been cited by other articles:
O'Brien, J. M., Chandiramani, M., Tribe, R., Shennan, A., Nicolaides, K. H., Celik, E., Fonseca, E. B., Rouse, D. J., Thom, E. A., Spong, C. Y., the NICHD Maternal Fetal Medicine Units Network,
(2007). Progesterone and Preterm Birth. NEJM
357: 2306-2307
[Full Text]
Odibo, A. O., Stamilio, D. M., Macones, G. A., Polsky, D.
(2006). 17{alpha}-hydroxyprogesterone Caproate for the Prevention of Preterm Delivery: A Cost-effectiveness Analysis.. Obstet Gynecol
108: 492-499
[Abstract][Full Text]
Meis, P. J., for the Society for Maternal-Fetal Medicine,
(2005). 17 Hydroxyprogesterone for the Prevention of Preterm Delivery. Obstet Gynecol
105: 1128-1135
[Abstract][Full Text]
Sanchez-Ramos, L., Kaunitz, A. M., Delke, I.
(2005). Progestational Agents to Prevent Preterm Birth: A Meta-Analysis of Randomized Controlled Trials. Obstet Gynecol
105: 273-279
[Abstract][Full Text]
BROWN, A. G., LEITE, R. S., STRAUSS, J. F. III
(2004). Mechanisms Underlying "Functional" Progesterone Withdrawal at Parturition. Ann. N. Y. Acad. Sci.
1034: 36-49
[Abstract][Full Text]
Meis, P. J., Klebanoff, M., Thom, E., Dombrowski, M. P., Sibai, B., Moawad, A. H., Spong, C. Y., Hauth, J. C., Miodovnik, M., Varner, M. W., Leveno, K. J., Caritis, S. N., Iams, J. D., Wapner, R. J., Conway, D., O'Sullivan, M. J., Carpenter, M., Mercer, B., Ramin, S. M., Thorp, J. M., Peaceman, A. M., the National Institute of Child Health and Human D,
(2003). Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate. NEJM
348: 2379-2385
[Abstract][Full Text]
Greene, M. F.
(2003). Progesterone and Preterm Delivery -- Deja Vu All Over Again. NEJM
348: 2453-2455
[Full Text]
Goldenberg, R. L., Rouse, D. J.
(1998). Prevention of Premature Birth. NEJM
339: 313-320
[Full Text]
